Anika Therapeutics Stock Alpha and Beta Analysis
| ANIK Stock | USD 15.91 0.70 4.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Anika Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Anika Therapeutics over a specified time horizon. Remember, high Anika Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Anika Therapeutics' market risk premium analysis include:
Beta 1.03 | Alpha (0.06) | Risk 2.17 | Sharpe Ratio (0.04) | Expected Return (0.08) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Anika |
Anika Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Anika Therapeutics market risk premium is the additional return an investor will receive from holding Anika Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Anika Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Anika Therapeutics' performance over market.| α | -0.06 | β | 1.03 |
Anika Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Anika Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Anika Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Anika Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Anika Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Anika Therapeutics shares will generate the highest return on investment. By understating and applying Anika Therapeutics stock market price indicators, traders can identify Anika Therapeutics position entry and exit signals to maximize returns.
Anika Therapeutics Return and Market Media
The median price of Anika Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 16.94 with a coefficient of variation of 4.27. The daily time series for the period is distributed with a sample standard deviation of 0.72, arithmetic mean of 16.88, and mean deviation of 0.63. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3 | 12/16/2024 |
2 | Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference | 12/23/2024 |
3 | Acquisition by David Colleran of 7662 shares of Anika Therapeutics subject to Rule 16b-3 | 12/24/2024 |
4 | Global Viscosupplementation Market to Hit Valuation US 11.31 Billion By 2033 Astute Analytica | 01/06/2025 |
5 | Dimensional Fund Advisors LP Reduces Stake in Anika Therapeutics Inc | 01/23/2025 |
6 | Are Investors Undervaluing Anika Therapeutics, Inc. By 48 | 02/06/2025 |
7 | Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference | 02/25/2025 |
8 | Avidity Biosciences, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/27/2025 |
9 | Anika Completes Divestiture of Parcus Medical | 03/07/2025 |
10 | Disposition of 20002 shares by Cheryl Blanchard of Anika Therapeutics subject to Rule 16b-3 | 03/10/2025 |
11 | Anika Therapeutics to Release Earnings on Wednesday | 03/11/2025 |
12 | Microsoft To Rally More Than 17 Here Are 10 Top Analyst Forecasts For Thursday | 03/13/2025 |
About Anika Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Anika or other stocks. Alpha measures the amount that position in Anika Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 80.9 | 78.76 | 70.88 | 54.36 | PTB Ratio | 1.51 | 1.56 | 1.41 | 1.73 |
Anika Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Anika Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anika Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Anika Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Anika Therapeutics. Please utilize our Beneish M Score to check the likelihood of Anika Therapeutics' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Anika Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Anika Therapeutics Backtesting, Anika Therapeutics Valuation, Anika Therapeutics Correlation, Anika Therapeutics Hype Analysis, Anika Therapeutics Volatility, Anika Therapeutics History and analyze Anika Therapeutics Performance. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Anika Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.